Browsing Resources in English by Subject "Antiviral Agents"
Now showing items 1-16 of 16
-
The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID‐19 infections
(2020-05-06)Severe acute respiratory syndrome coronavirus‐2 (SARS CoV‐2) is the causative agent of the coronavirus disease‐2019 (COVID‐19) pandemic. Coronaviruses enter cells via fusion of the viral envelope with the plasma membrane ... -
Assessment of Evidence for COVID-19-Related Treatments: Updated 4/17/2020
(2020-04-17)The information contained in this evidence table is emerging and rapidly evolving because of ongoing research and is subject to the professional judgment and interpretation of the practitioner due to the uniqueness of each ... -
Clinical trials for the prevention and treatment of COVID ‐19: current state of play
(2020-06-27)Since coronavirus disease 2019 (COVID ‐19) emerged in Wuhan, China in December 2019 and spread around the world, over 1100 clinical studies have been registered globally on clinical trials registries, including over 500 ... -
Coronavirus disease 2019 (COVID-19) pandemic and pregnancy
(2020-03-23)The current coronavirus disease 2019 (COVID-19) pneumonia pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading globally at an accelerated rate, with a basic reproduction number ... -
Covid2019 / SARSCoV2 coronavirus antivirals
(2020-04-20)Includes: Interferons, Nucleoside analogs, Protease inhibitors, Furin Convertase Cleavage inhibitors, Reverse transcriptase inhibitors, RNA Polymerase/Synthesis Inhibitors, Neuraminidase inhibitors, Angiotensin II receptor ... -
Directly Acting Antivirals for COVID-19: Where Do We Stand?
(2020-08-05)The outbreak of a novel coronavirus (SARS-CoV-2) in Wuhan, China in December 2019 has now become a pandemic with no approved therapeutic agent. At the moment, the genomic structure, characteristics, and pathogenic mechanisms ... -
Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID‐19)
(2020-03-27)Background: At present, the severity of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been a focal point. Methods: To assess the factors associated with severity and prognosis of ... -
Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials
(2020-10-15)Several randomized controlled trials (RCTs) were conducted to investigate the effect of remdesivir for patients with COVID-19, but their results were conflicting. Thus, we conducted a network meta-analysis comparing the ... -
Efficacy and safety of arbidol in the treatment of novel coronavirus pneumonia: a systematic review based on current and previous antiviral therapy
(2020)Objective: To systematically evaluate the efficacy and safety of arbidol in the treatment of novel coronavirus pneumonia (COVID-19). Methods: Randomized controlled trials (RCTs), cohort studies, and case-control studies ... -
Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis
(2020-09-24)Background: The COVID-19 causing coronavirus is an enveloped RNA virus that utilizes an enzyme RNA dependent RNA polymerase for its replication. Favipiravir (FVP) triphosphate, a purine nucleoside analog, inhibits that ... -
An Infectious cDNA Clone of Zika Virus to Study Viral Virulence, Mosquito Transmission, and Antiviral Inhibitors
(2016-07)The Asian lineage of Zika virus (ZIKV) has recently caused epidemics and severe disease. Unraveling the mechanisms causing increased viral transmissibility and disease severity requires experimental systems. We report an ... -
Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: a pilot retrospective study
(2020-04-29)Objectives: This study aimed to evaluate the antiviral efficacy of lopinavir/ritonavir alone or combined with arbidol in the treatment of hospitalized patients with common coronavirus disease-19 (COVID-19). Methods: In ... -
Lopinavir-ritonavir for COVID-19: A living systematic review
(2020-07-15)Objective: Provide a timely, rigorous, and continuously updated summary of the evidence on the role of lopinavir/ritonavir in the treatment of patients with COVID-19. Methods: We conducted searches in the special L·OVE ... -
A Plausible Penny Costing Effective Treatment for Corona Virus - Ozone Therapy
(2020-03)Many viruses require reduced sulfhydryl groups for cell fusion and entry. Corona viruses, including SARS-CoV-2 (the cause of the condition now named coronavirus disease 2019 or COVID-19), are rich in cysteine, which residues ... -
Repositioned chloroquine and hydroxychloroquine as antiviral prophylaxis for COVID-19: A protocol for rapid systematic review of randomized controlled trials
(2020-04-23)Since the SARS-CoV-2 outbreak rapidly evolved into a pandemic, there is an urgent need for rapid development, identification and confirmation of efficacious antiviral prophylaxis. In this setting, the existing drugs ... -
Spotlight of Remdesivir in Comparison with Ribavirin, Favipiravir, Oseltamivir and Umifenovir in Coronavirus Disease 2019 (COVID-19) Pandemic
(2020-04-01)2019-nCoV pandemic has influenced on millions of people’s life across the world, which is caused severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or coronavirus disease 2019 (COVID-19). Today, no effective ...